Articles related to VACCINES
Nose Spray Vaccines Could Quash COVID Virus Variants
Although vaccinations to the arm can still prevent serious illness, their ability to ward off infection completely has been diminished. And part of the reason may be the location of the vaccines, which some scientists now want to change by delivering inoculations to the site where the virus first makes contact: the nose. Three separate nasal sprays, now in advanced trials, could trigger stronger immune responses in people who have COVID-19.
Allergy & Immunology May 10th 2022
Moderna COVID-19 Vaccine May Be More Effective in CLL Patients
In a single-center study of 240 patients with lymphoid malignancies — 181 with CLL, 21 with WM, and 38 with other non-Hodgkin lymphomas (NHLs) – patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine compared to the Pfizer-BioNTech vaccine. This superior response was demonstrated in both treatment naïve and treated CLL populations in the study.
Oncology, Medical April 12th 2022
The Neurological Safety of COVID-19 Vaccines
Two large scale studies featured in The British Medical Journal concluded that mRNA-based vaccines do not appear to be associated with an increased risk of neurological adverse events; and secondly, that risks of Guillain-Barré syndrome and Bell’s palsy are slightly increased after immunization. Overall, the findings of both studies are reassuring about the safety of the vaccines, particularly compared with the observed risks associated with SARS-CoV-2 infection.
Neurology March 29th 2022
Risk for Shoulder Conditions After Vaccination: A Population-Based Study Using Real-World Data
Given the high burden of shoulder conditions, clinicians should pay attention to any factors that may further increase risks. This study found a low incidence of shoulder issues following vaccination in the deltoid muscle but does delineate population at higher risk for developing these issues.
Family Medicine/General Practice March 29th 2022
The Incidence of SARS-CoV-2 Reinfection in Persons with Naturally Acquired Immunity with and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine
This Annals of Internal Medicine study reports an 82% decreased risk for reinfection for those previously infected and then vaccinated, versus those previously infected but who remained unvaccinated. Reinfection in both groups was relatively rare.
Allergy & Immunology February 23rd 2022
COVID-19: Whatever Happened to the Novavax Vaccine?
At the outset of the pandemic, biotechnology company Novavax was one of the frontrunners to bring a vaccine against COVID-19 to market. But nearly two years later, Novavax’s vaccine has yet to appear. In a compelling article, the BMJ details the repeated delays and setbacks that have torpedoed Novavax’s once-promising vaccine candidate and rendered it unnecessary now that other vaccines from Pfizer, Moderna, and AstraZeneca flood the global marketplace.
Allergy & Immunology December 14th 2021